VERU: Veru Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
60 institutions reported holding $8.56M of Veru Inc. on Form 13F (58 the quarter before). 12 opened a new position and 10 sold out. Shares held by institutions: -17%.
| Largest holders | Shares | Value |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 698,439 | $2.19M |
| Alyeska Investment Group, L.P. | 238,556 | $747K |
| OPPENHEIMER & CO INC | 210,843 | $660K |
| BlackRock, Inc. | 167,084 | $523K |
| RENAISSANCE TECHNOLOGIES LLC | 164,450 | $515K |
| GEODE CAPITAL MANAGEMENT, LLC | 155,076 | $486K |
| Summit Financial, LLC | 141,865 | $444K |
| JANE STREET GROUP, LLC | 127,853 | $400K |
| RAYMOND JAMES FINANCIAL INC | 84,969 | $266K |
| VANGUARD FIDUCIARY TRUST CO | 81,230 | $254K |
Clinical trial readouts
1 Phase 2 or 3 trials by Veru Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-10 (est.) | Enobosarm | Obesity & Overweight | Phase 2 | 239 | Enrollment complete | NCT07446998 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.